Hydrochlorothiazide, valsartan (Co-diovan, Co-tareg, Co-diovan Plus, Co-tareg Plus, Co-migroben, Co Migroben)
Hydrochlorothiazide, valsartan
Novartis South Africa (Pty) Ltd
Registration
- Applicant
- Novartis South Africa (Pty) Ltd
- Certificate holder
- Novartis South Africa (Pty) Ltd.
- Registrations
- 11
- Schedule source
- SAHPRA documentation
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Co-diovan EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 12,5 mg VALSARTAN 80,0 mg | 80/12.5, 160/12.5, 320/12.5, 320/25 mgFilm-coated tablets. | 32033632/7.1.3/0336Approved 12 March 2025 | Registered | S3 | PIPIL |
| Co-diovan 160 EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 12,5 mg VALSARTAN 160,0 mg | 160 | 34044134/7.1.3/0441 | Registered | S3 | None |
| Co-tareg 80 EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 12,5 mg VALSARTAN 80,0 mg | 80 | 35027635/7.1.3/0276 | Registered | S3 | None |
| Co-diovan 160 plus EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 25,0 mg VALSARTAN 160,0 mg | 160 | 37022537/7.1.3/0225 | Cancelled | S3 | None |
| Co-diovan 320/12,5 tablets EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 12,5 mg VALSARTAN 320,0 mg | 320/12,5Tablets | 41014741/7.1.3/0147 | Registered | S3 | None |
| Co-diovan 320/25 tablets EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 25,0 mg VALSARTAN 320,0 mg | 320/25Tablets | 41014841/7.1.3/0148 | Registered | S3 | None |
| Co-tareg 160 EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 12,5 mg VALSARTAN 160,0 mg | 160 | 41074341/7.1.3/0743 | Registered | S3 | None |
| Co-tareg 160 plus EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 25,0 mg VALSARTAN 160,0 mg | 160 | 41074441/7.1.3/0744 | Registered | S3 | None |
| Co-migroben 80/12,5 tablet EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 12,5 mg VALSARTAN 80,0 mg | 80/12,5Tablet | 43008343/7.1.3/0083 | Registered | S3 | None |
| Co migroben 160/12,5 EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 12,5 mg VALSARTAN 160,0 mg | 160/12,5Film-coated tablets. | 43008443/7.1.3/0084Approved 12 March 2025 | Registered | S3 | PIPIL |
| Co migroben 160/25 EACH TABLET CONTAINS HYDROCHLOROTHIAZIDE 25,0 mg VALSARTAN 160,0 mg | 160/25Film-coated tablets. | 43008543/7.1.3/0085Approved 12 March 2025 | Cancelled | S3 | PIPIL |
Regulatory status
Where S3 sits on the scale
Needs a doctor's prescription, dispensed by a pharmacist.
Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S3, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Hydrochlorothiazide, valsartan
S3: Hydrochlorothiazide
Consolidated Schedules 06 July 2026, line 3721
S3: Valsartan
Consolidated Schedules 06 July 2026, line 4376
Pharmacological class: Other hypotensives. (class 7.1.3)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
Schedule Verification
This medication's schedule (S3) has been verified from official SAHPRA documents with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.